Introduction
============

Liver cancer is more common in men than in women, and is the second leading cause of cancer-associated mortality worldwide in men living in less developed countries ([@b1-or-41-03-1586]). It is estimated that \~50% of newly diagnosed cancer cases and mortalities globally occurred in China alone in 2012, which equates to approximately 391,250 new liver cancer cases and 372,750 mortalities ([@b1-or-41-03-1586]). Hepatocellular carcinoma (HCC) accounts for the majority (70--90%) of primary liver cancer cases worldwide ([@b2-or-41-03-1586]). Previous epidemiological surveys have revealed that chronic hepatitis B or C viral infection, cirrhosis, exposure to aflatoxin B1, obesity, chronic alcohol consumption and diabetes mellitus, as well as metabolic abnormalities including haemochromatosis and α1-antitrypsin deficiency, are common and significant risk factors for HCC development ([@b3-or-41-03-1586]--[@b5-or-41-03-1586]). Furthermore, recent studies indicate that approximately 1,000,000 new HCC cases are diagnosed each year worldwide, with the same incidence and morbidity rate, indicating that HCC diagnosis is typically at the advanced stage and prognosis remains poor ([@b6-or-41-03-1586],[@b7-or-41-03-1586]). Despite advances in diagnosis, prevention and treatment, including ultrasonography, multiphase computerized tomography, magnetic resonance imaging, surgical resection, liver transplantation, transarterial chemoembolization, radiofrequency ablation and transarterial radiation, percutaneous ablation and systemic therapy, the prognosis for HCC patients remains unsatisfactory ([@b8-or-41-03-1586]). The 5-year relative survival rate is approximately 7% ([@b9-or-41-03-1586]). Therefore, identification of novel biomarkers for the early diagnosis of HCC is vital and may improve HCC prognosis.

At present, many reports have focused on the identification of prognosis-associated biomarkers The role of astrocytic phosphoprotein PEA-15 in HCC has been evaluated and may be a novel target for HCC treatment, as well as a predictive biomarker for HCC patient prognosis ([@b10-or-41-03-1586]). Furthermore, it has been suggested that CKLF-like MARVEL transmembrane domain-containing protein 5 may function as a tumor suppressor in human HCC and represent a valuable therapeutic target ([@b11-or-41-03-1586]). microRNA (miR)-182-5p is recognized as a potential predictive biomarker for the early recurrence of HCC ([@b12-or-41-03-1586]). Currently, DNA microarray approach has been used to investigate the genetic features of HCC in molecular biology ([@b13-or-41-03-1586]). Accumulating evidence regarding gene expression in HCC has demonstrated that a variety of differentially expressed genes (DEGs) may be involved in the process of hepatocarcinogenesis ([@b14-or-41-03-1586]). The combination of microarray techniques and bioinformatic analysis makes it conceivable to use DEGs in one or more chips to detect potential predictive biomarkers for several types of malignancies ([@b15-or-41-03-1586]). Therefore, the present study focused on DEGs in microarrays and aimed to identify potential predictive biomarkers for patients with HCC.

Materials and methods
=====================

### Data collection and processing

GEO2R ([www.ncbi.nlm.nih.gov/geo/geo2r/](www.ncbi.nlm.nih.gov/geo/geo2r/)) was initially used to identify DEGs in the GSE36376 gene expression profile in the Gene Expression Omnibus (GEO) database ([@b16-or-41-03-1586]). The GSE36376 dataset ([www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36376](www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36376)) is embedded in the platform GPL10558 (Illumina HumanHT-12 v4 Expression Beadchip) and includes 240 tumor tissues and 193 adjacent non-tumor tissues of two gene expression by array sets: A training set and validation set ([@b17-or-41-03-1586]).

Next, DEGs from the GSE36376 profile were acquired using the GEO2R tool with the criteria of \|log fold change\|≥2 and P≤0.05. Furthermore, the Cytoscape software (version 3.6.0) plugin, CentiScaPe (version 2.2), was employed to identify the top 10 hub genes in these DEGs on the basis of the following centralities: degree, betweenness and closeness ([@b18-or-41-03-1586]).

### Hub gene expression, survival and stratified analysis

The expression levels of 10 hub genes in multiple organs, as well as in tumor and non-tumor tissues were obtained from the GTEx portal ([www.gtexportal.org/home](www.gtexportal.org/home)) and the Gene Expression Profiling Interactive Analysis (GEPIA; [gepia.cancer-pku.cn/index.html](gepia.cancer-pku.cn/index.html)) server ([@b19-or-41-03-1586]). Protein expression levels of the hub genes in liver tissue were obtained from The Human Protein Atlas ([www.proteinatlas.org](www.proteinatlas.org)) ([@b20-or-41-03-1586]). A co-expression matrix was constructed using R (version 3.5.0; [www.r-project.org](www.r-project.org)) to show Pearson correlations between two of these genes.

In addition, hub genes were further analyzed for their prognostic values using The Cancer Genome Atlas database ([cancergenome.nih.gov/](cancergenome.nih.gov/)). The clinical characteristics of 360 HCC patients, including age, sex, race and tumor stage, were obtained and used in the analysis. Gene expression data were downloaded from the OncoLnc website ([www.oncolnc.org](www.oncolnc.org)) at median cut off. In addition, clinical data with statistically significant P-values (≤0.05) were adjusted for further analysis to identify prognosis-associated genes. For the above identified genes, clinical data were stratified for further analysis.

### Hub gene mutational and transcriptional analysis

The mutation status of hub genes using the cBioPortal website ([www.cbioportal.org/](www.cbioportal.org/)) ([@b21-or-41-03-1586],[@b22-or-41-03-1586]). Furthermore, transcripts per million (TPM) of the hub genes in liver tissues were analyzed to identify transcription levels at the log scale \[Log~2~ (TPM+1)\] using the GEPIA website ([gepia.cancer-pku.cn/index.html/](gepia.cancer-pku.cn/index.html/)) ([@b19-or-41-03-1586]).

### Construction of risk score model and nomogram

A risk score model was constructed based on the expression levels of prognosis-associated genes and the contribution coefficient (β) of the multivariate Cox proportional hazards regression model. The formula of the model was as follows: risk score=expression of gene~1~ × β~1~ of gene~1~ + expression of gene~2~ × β~2~ of gene~2~ + ... + expression of gene~n~ × β~n~ of gene~n~. The risk score was then divided into high and low risk groups with the same cut-off criteria of gene expression. A Kaplan-Meier survival curve was drawn to predict patient survival. Prognostic receiver operating characteristic (ROC) curves were then created at 1--5 years.

A nomogram was also constructed based on seven prognosis-associated hub genes, clinical factors and tumor stage, to obtain patient survival at 1, 3 and 5 years. The contribution of each factor was limited to a maximum of 100 points.

### Gene-gene and protein-protein interactions (PPI) network construction and functional enrichment analysis

To identify the biological processes and metabolic pathways of these hub genes, enrichment analysis of Gene Ontology (GO) was performed, including biological process (BP), cellular component (CC), and molecular function (MF), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using The Database for Annotation, Visualization and Integrated Discovery (DAVID; [david.ncifcrf.gov/](david.ncifcrf.gov/)) ([@b15-or-41-03-1586],[@b23-or-41-03-1586]). In addition, visualized GO results were presented by the Cytoscape BinGO plugin version 3.6.0 ([@b18-or-41-03-1586],[@b24-or-41-03-1586]). Gene-gene interaction networks were constructed using the GeneMANIA plugin (version 3.4.1) in Cytoscape software version 3.6.0 ([@b25-or-41-03-1586]). The PPI network depicted interactions among these proteins and was constructed using the Search Tool for the Retrieval of Interacting Genes website ([string-db.org/cgi/input.pl](string-db.org/cgi/input.pl)) ([@b26-or-41-03-1586]).

### Statistical analysis

Kaplan-Meier survival analysis by log rank test was used to calculate the median survival time (MST). Univariate and multivariate Cox proportional hazards models were used to calculate the hazard ratio (HR) and 95% confidence interval (CI). P≤0.05 was considered to indicate a statistically significant difference. Box plots by unpaired t-test, survival curves and ROC curves including area under the curve (AUC) were produced using GraphPad version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical analysis was performed using SPSS software version 16.0 (SPPS, Inc., Chicago, IL, USA).

Results
=======

### Processing of DEGs and hub genes

A total of 71 DEGs were obtained from the GSE36376 dataset and the top 10 hub genes were identified. These 10 hub genes included cytochrome P450 family 2 subfamily E member 1 (*CYP2E1*), tyrosine aminotransferase (*TAT*), cytochrome P450 family 2 subfamily A member 6 (*CYP2A6*), cytochrome P450 family 8 subfamily B member 1 (*CYP8B1*), cytochrome P450 family 2 subfamily C member 9 (*CYP2C9*), hydroxysteroid 11-β dehydrogenase 1 (*HSD11B1*), hydroxysteroid 17-β dehydrogenase 13 (*HSD17B13*), solute carrier family 22 member 1 (*SLC22A1*), cytochrome p450 family 2 subfamily C member 8 (*CYP2C8*) and alcohol dehydrogenase 4 (class II), pi polypeptide (*ADH4*). Detailed results are shown in [Table I](#tI-or-41-03-1586){ref-type="table"}.

### Analysis of hub gene expression, mutation and transcription

Hub gene expression in tumor tissues was downregulated compared with normal tissues in all cases ([Fig. 1](#f1-or-41-03-1586){ref-type="fig"}). However, only *CYP2A6, CYP2C8, CYP2E1, HSD17B13* and *SLC22A1* had a significant alteration in expression (P\<0.05). Tissue expression data indicated that all of the hub genes were highly expressed in liver tissue ([Fig. 2](#f2-or-41-03-1586){ref-type="fig"}). Mutation analysis of hub genes revealed that mutations were present in different ratios ([Fig. 3A](#f3-or-41-03-1586){ref-type="fig"}). At 11%, *HSD11B1* was the most significant in terms of mutation ratio, of which the majority were amplification mutations. Transcriptional analysis ([Fig. 3B](#f3-or-41-03-1586){ref-type="fig"}) demonstrated that all hub genes were differentially transcribed in tumor and normal tissues. Furthermore, normal tissues had consistently high TPM in the 10 hub genes. Detailed results are shown in [Fig. 3](#f3-or-41-03-1586){ref-type="fig"}.

Protein expression data indicated that eight proteins were highly expressed in liver tissue, excluding *TAT* and *CYP8B1* (data not shown; [Fig. 4](#f4-or-41-03-1586){ref-type="fig"}), which was similar to the tissue expression results.

### Demographic and clinicopathological characteristics

A total of 360 HCC patients were included in the dataset. Survival analysis indicated that tumor stage showed statistical significance (log-rank P\<0.0001), but all other factors were not significant (log-rank P\>0.05; [Table II](#tII-or-41-03-1586){ref-type="table"}).

### Expression levels and survival analysis of hub genes

In the univariate survival analysis, *ADH4, CYP2C8, CYP2C9, CYP2E1, CYP8B1, HSD17B13, SLC22A1* and *TAT* were significant (P≤0.05; [Table III](#tIII-or-41-03-1586){ref-type="table"} and [Fig. 5](#f5-or-41-03-1586){ref-type="fig"}). Following adjustment for tumor stage, *ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT* and *HSD17B13* were significant (P≤0.05; [Table III](#tIII-or-41-03-1586){ref-type="table"}) while *CYP2A6, CYP2E1, HSD11B1* were not significant (P\>0.05). All hub genes were significantly different when comparing high and low expression levels (P\<0.0001; [Fig. 6A](#f6-or-41-03-1586){ref-type="fig"}).

### Stratified analysis of prognosis-associated genes

In the stratification of tumor stage, high expression levels of *CYP2C8, CYP2C9, SLC22A1, TAT* and *HSD17B13* had tumor suppressor roles in stages I and II (P≤0.05) while high expression levels of *ADH4, CYP2C8, CYP8B1, SLC22A1, TAT* and *HSD17B13* had tumor suppressor roles in stages III and IV (P≤0.05). Detailed results are presented in [Tables IV](#tIV-or-41-03-1586){ref-type="table"} and [V](#tV-or-41-03-1586){ref-type="table"}.

### Hub gene co-expression and Pearson correlation analysis

The majority of hub genes showed significant Pearson correlations with other genes. For example, *CYP2E1* was positively correlated with *CYP2C8, CYP2C9, CYP8B1, ADH4* and *HSD11B1*, and negatively correlated with *CYP2A6* and *HSD17B13*. Detailed results are presented in [Fig. 6B](#f6-or-41-03-1586){ref-type="fig"}.

In the PPI network, most of the hub genes exhibited complicated interactive co-expression relationships, with the exception of HSD11B1, which was co-expressed with HSD17B13 alone ([Fig. 6C](#f6-or-41-03-1586){ref-type="fig"}). In the gene-gene interaction network, each gene was co-expressed with at least two other genes ([Fig. 6D](#f6-or-41-03-1586){ref-type="fig"}).

### Risk score model and nomogram construction

A risk score model was constructed using the aforementioned formula, which contained risk score ranking, survival status and heat maps of gene expressions ([Fig. 7A](#f7-or-41-03-1586){ref-type="fig"}). The Kaplan-Meier plot revealed that the percent survival difference between the low and high risk groups was significant ([Fig. 7B](#f7-or-41-03-1586){ref-type="fig"}). ROC curves were then constructed to evaluate the prognostic values of the model. In the 1--5 year ROC curves, all AUCs were above 0.6 ([Fig. 7C](#f7-or-41-03-1586){ref-type="fig"}), which shows that this model was useful for prognosis prediction. In the comparison of high and low risk score groups, all of the comparisons showed significant P-values (all P\<0.001; [Fig. 7D](#f7-or-41-03-1586){ref-type="fig"}).

The contributions of each factor were present in the nomogram ([Fig. 8](#f8-or-41-03-1586){ref-type="fig"}). In detail, tumor stages III and IV showed the maximum 100 points. Unlike the other genes, high expression levels of *CYP8B1* had a high number of points. High points typically indicated low survival probability at 1, 3 and 5 years. As expected, there was a high probability of survival prediction at 1 year compared with 5 years.

### Hub genes enrichment analysis

GO analysis revealed that genes were significantly enriched in the terms such as 'oxidation-reduction process', the 'epoxygenase P450 pathway', 'metbolism of xenobiotics by cytochrome P450', 'chemical carcinogenesis', 'drug metabolic processes' and 'organelle membranes' ([Fig. 9](#f9-or-41-03-1586){ref-type="fig"}).

BP terms, including 'exogenous drug catabolic process', 'drug catabolic process', 'secondary metabolic process' and 'oxidation reduction', were significantly enriched ([Fig. 10](#f10-or-41-03-1586){ref-type="fig"}). In CC terms, 'subsynaptic reticulum', 'endoplasmic reticulum', 'microsome' and 'vesicular fraction', were enriched ([Fig. 11](#f11-or-41-03-1586){ref-type="fig"}). 'Oxygen binding', 'iron ion binding', 'heme binding', 'electron carrier activity' and 'oxidoreductase activity', were enriched in terms of MF ([Fig. 12](#f12-or-41-03-1586){ref-type="fig"}).

Discussion
==========

In the present study, DEGs were analyzed in microarrays to identify hub genes. The top 10 hub genes in the GSE36376 dataset were examined for their prognostic prediction value in HCC. A total of seven genes, including *ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT* and *HSD17B13*, were identified as potential prognostic biomarkers. In addition, high expression levels of these hub genes were associated with tumor suppressing roles in HCC. Stratified analysis of clinical factors further revealed their prognostic values in subgroups. A risk score model for patient survival was constructed and evaluated, which confirmed its value for assessing prognosis. A nomogram was created to identify the degree of the contribution made by each factor. Enrichment analysis of the hub genes highlighted the metabolic pathways and biological processes that the hub genes were involved in, which may provide clues into the exact mechanisms of HCC development.

Valuable data in gene microarrays may be lost due to potentially unpredictable problems with the samples when the results of a single piece of research are analyzed ([@b27-or-41-03-1586]). Furthermore, using a Student\'s t-test to analyze microarray data has several limitations ([@b27-or-41-03-1586]). Small sample sizes may lead to unreliable variance estimation, leading to a high false-positive rate, while some significant and reliable differences in expression may be missed ([@b28-or-41-03-1586]). However, in the present study, analyzing microarray data from a study with a large sample size, allowed the acquisition of potentially useful information for further analysis. In total, 433 samples from the GSE36376 dataset were analyzed to obtain DEGs, in order to determine potential serum biomarkers for HCC diagnosis and prognosis. Focused on an Asian population, the present study also searched for DEGs using the GEO2R online resource. The top 10 hub genes in these DEGs were selected for further analysis, and seven of these hub genes, *ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT* and *HSD17B13*, were confirmed to have prognostic value in HCC.

The human ADH4 enzyme is encoded by the *ADH4* gene, which maps to 4q22 within the ADH gene cluster ([@b29-or-41-03-1586]). Previous studies have revealed that a *ADH4* gene variant confers risk for alcohol dependence (AD) and related traits in European Americans and African Americans ([@b29-or-41-03-1586]). Edenberg *et al* ([@b30-or-41-03-1586]) reported that 16 single nucleotide polymorphisms (SNP) of *ADH4*, including rs2226896, are associated with AD, in an independent collaborative study on the genetics of alcoholism. Edenberg *et al* ([@b31-or-41-03-1586]) showed that ADH4 promoter variant −75A/C (rs800759), which could alter ADH4 enzyme expression levels significantly, as well as the 159A/G variant were significantly linked to AD in European Americans and African Americans in a Brazilian population ([@b31-or-41-03-1586]). Previous studies have reported that *ADH4* may be associated with cluster headaches and personality traits such as agreeableness and extraversion ([@b32-or-41-03-1586],[@b33-or-41-03-1586]). In addition, polymorphisms in the *ADH4* gene are associated with a decreased risk of ovarian cancer ([@b34-or-41-03-1586]) and an increased risk of upper aerodigestive tract cancer ([@b35-or-41-03-1586]), which suggests that the *ADH4* may be involved in tumorigenesis. Wei *et al* ([@b36-or-41-03-1586]) found that *ADH4* mRNA expression in HCC is significantly lower than that in non-cancerous tissue, and ADH4 protein expression is also reduced in HCC, which indicates that ADH4 may serve as a tumor suppressor. These findings are consistent with the results of the present study, where ADH4 was identified as a potential prognostic biomarker for HCC.

The CYP2 family contains many subfamilies, including CYP2A, CYP2B, CYP2C, CYP2D, CYP2E and CYP2F ([@b37-or-41-03-1586]). *CYP2C8* and *CYP2C9* are members of the CYP2C subfamily that are localized in a single gene locus on chromosome 10 ([@b38-or-41-03-1586],[@b39-or-41-03-1586]). CYP2C8 shares sequence homology with CYP2C9, that metabolizes several drugs including analgesics ([@b40-or-41-03-1586]), antidiabetic and cholesterol-lowering drugs ([@b41-or-41-03-1586]). CYP2C9 metabolizes the majority of angiotensin II type 1 receptor blockers ([@b42-or-41-03-1586]) and neurological drugs ([@b43-or-41-03-1586]). In addition, CYP2C8 has been associated with an increased risk of essential hypertension and coronary artery disease in Bulgarian patients ([@b44-or-41-03-1586]), anemia ([@b45-or-41-03-1586]), vascular inflammatory disease ([@b46-or-41-03-1586]) and breast cancer ([@b47-or-41-03-1586]). It has been reported that CYP2C9 downregulation by miR-128-3p is associated with HCC ([@b48-or-41-03-1586]). In addition, we have previously reported that analysis of CYP2C8 and CYP2C9 expression in combination is better than analyzing them in isolation ([@b37-or-41-03-1586]).

CYP8B1 is predominantly expressed in hepatocytes in a homogenous pattern ([@b49-or-41-03-1586]) and is involved in bile acid synthesis of bile acids ([@b50-or-41-03-1586]). Overexpression of CYP8B1 alone or in combination with CYP7A1, but not of CYP7A1 alone, reverses obeticholic acid-induced alterations in bile acid levels (taurocholic acid), bile acid composition (taurocholic acid and α/β-muricholic acids) and cholesterol absorption ([@b51-or-41-03-1586]). The SNP rs3732860 in the 3′-untranslated region of the *CYP8B1* gene is linked to gallstone disease risk in the Chinese Han population ([@b52-or-41-03-1586],[@b53-or-41-03-1586]). However, the function of CYP8B1 in cancer remains elusive. The present study indicated that CYP8B1 may serve as a potential biomarker for HCC, and may be involved in tumor initiation and development.

*SLC22A1* has the ability to encode solute carrier family 22 member 1, which is not only an uptake transporter but also has a predictive value for the molecular response to imatinib mesylate therapy ([@b54-or-41-03-1586]). Patients who experience a major molecular response have higher *SLC22A1* expression compared with those without a major molecular response ([@b55-or-41-03-1586]). *SLC22A1-ABCB1* haplotype profiles can predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia ([@b56-or-41-03-1586]). Indirect *SLC22A1* gene upregulation by dexamethasone may be caused by glucocorticoid receptor-induced hepatocyte nuclear factor-4α expression in primary human hepatocytes, but not in hepatocyte-derived tumor cell lines ([@b57-or-41-03-1586]). HCC and cholangiocarcinoma development is typically accompanied by decreased SLC22A1 expression, which may significantly alter the ability of sorafenib to reach active intracellular concentrations in these tumors ([@b58-or-41-03-1586]). Downregulated SLC22A1 expression is associated with tumor progression and decreased survival in patients with cholangiocellular carcinoma ([@b59-or-41-03-1586]). However, to the best of our knowledge, the relationship between SLC22A1 and HCC patient prognosis has not been reported. The present study demonstrated that SLC22A1 may be a predictive biomarker for HCC.

TAT is associated with the catalyzing the transamination of tyrosine and other aromatic amino acids and plays a role in recovery from tyrosinemia type II, hepatitis and hepatic carcinoma ([@b60-or-41-03-1586]). Deficiency of TAT causes marked hypertyrosinemia, which leads to painful palmoplantar hyperkeratosis, pseudodendritic keratitis, and variable mental retardation ([@b61-or-41-03-1586]). Recurrent mutation of the TAT gene has been reported in those affected by Richner-Hanhart syndrome ([@b62-or-41-03-1586]). Fu *et al* ([@b63-or-41-03-1586]) reported that downregulation of TAT at a frequently deleted region, 16q22, contributes to the pathogenesis of HCC, and it was demonstrated that TAT is a novel tumor suppressor gene. This finding is consistent with the results of the present study, and may be used as an effective serum biomarker for HCC.

Su *et al* ([@b64-or-41-03-1586]) reported that *HSD17B13* is upregulated in the livers of patients with non-alcoholic fatty liver disease. HSD17B13 expression is localized to liquid droplets ([@b65-or-41-03-1586]). In addition, Chen *et al* ([@b66-or-41-03-1586]) reported that HSD17B13 is downregulated in HCC, and has a tumor suppressor role via inhibition of HCC progression and recurrence ([@b66-or-41-03-1586]). This finding is in accordance with the results of the present study, where it was concluded that HSD17B13 may serve as a potential predictive biomarker for HCC.

In regards to metabolic pathways, our previous study demonstrated that the CYP2C subfamily members are involved in chemical carcinogenesis ([@b37-or-41-03-1586]). The formation of DNA adducts, dG-C8-IQ, dG-N-IQ, dG-C8-MeIQx and dG-N-MeIQx, may induce liver, colon lung and breast cancer tumorigenesis ([@b37-or-41-03-1586]). The present study found that the identified hub genes were also enriched in chemical carcinogenesis. Additionally, gene were enriched in 'drug metabolism-cytochrome P450', 'metabolism of xenobiotics by cytochrome P450', 'retinol metabolism', 'linoleic acid metabolism', 'arachidonic acid metabolism', 'tyrosine metabolism', and 'steroid hormone biosynthesis'. These metabolic processes and pathways provide evidence that the hub genes may be involved in hepatocarcinogenesis.

There are some limitations to the present study. First, larger samples that include other populations are required to validate the findings of the present study. Second, an increased number of valid clinical factors, such as race, drinking status, smoking status, cirrhosis, Barcelona-Clinic liver cancer staging, hepatitis infection status, antiviral therapy, α-fetoprotein levels and microvascular invasion, should be included in the analysis. Third, functional validation in a well-designed clinical trial is required to examine the biological behavior of prognosis-associated genes on HCC initiation and progression. As the present study explored the potential prognostic biomarkers for HCC, the identification and clinical significance of targeted drugs was not investigated in the present study. Thus, it is crucial to focus future studies on these topics.

The present study indicated that low gene expression of *ADH4, CYP2C8, CYP2C9, CYP8B1, SLC22A1, TAT* and *HSD17B13* are predictors of poor prognosis in HCC. Further functional trials and identification of targeted drugs for these hub genes is warranted to determine clinical application. In detail, trials *in vivo* and *in vitro* should be conducted to explore biological behavior, such as invasion, metastasis and proliferation ability. Then, the influence potential drugs on their target genes should be validated, to determine whether targeted overexpression of these genes improve HCC prognosis.
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![Mutational and transcriptional analysis of hub genes. (A) Mutational analysis including missense mutation, deep deletion and amplification of the 10 hub genes. (B) Transcriptional analyses (TPM) of the 10 hub genes in tumor and normal tissues. TPM, transcripts per million; *CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *TAT*, tyrosine aminotransferase; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.](OR-41-03-1586-g02){#f3-or-41-03-1586}

![Immunohistochemistry results of protein expression levels of hub genes *ADH4, CYP2A6, CYP2C8, CYP2C9, CYP2E1, HSD11B1, HSD17B13* and *SLC22A1* in normal liver tissues. *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1.](OR-41-03-1586-g03){#f4-or-41-03-1586}

![Kaplan-Meier plots of hub genes *ADH4, CYP2A6, CYP2C8, CYP2C9, CYP2E1, CYP8B1, HSD11B1, HSD17B13, SLC22A1* and *TAT*. *CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *TAT*, tyrosine aminotransferase; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.](OR-41-03-1586-g04){#f5-or-41-03-1586}

![Expression levels, Pearson\'s correlations and expression network analysis of hub genes. (A) Relative mRNA expression levels in low expression and high expression groups. (B) Pearson correlation analysis of hub genes. Blue indicates positive correlation and red indicates negative correlation. (C) Protein-protein interaction network and (D) Gene-gene co-expression network of hub genes. \*\*P\<0.01, \*\*\*P\<0.001, \*\*\*\*P\<0.0001. *CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *TAT*, tyrosine aminotransferase; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.](OR-41-03-1586-g05){#f6-or-41-03-1586}

![Risk score model, survival plot, ROC curves and boxplot. (A) Risk score model plot including risk score ranking, survival status and heatmap. (B) Kaplan-Meier plot of the risk score model. (C) ROC curves for 1-, 2-, 3-, 4- and 5-year survival rates from the risk score model. (D) Boxplot of risk score groups. \*\*\*\*P\<0.0001. ROC, receiver operating characteristic; *TAT*, tyrosine aminotransferase; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.](OR-41-03-1586-g06){#f7-or-41-03-1586}

![Nomogram for predicting HCC prognosis. *TAT*, tyrosine aminotransferase; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *SLC22A1*, solute carrier family 22 member 1; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.](OR-41-03-1586-g07){#f8-or-41-03-1586}

![Enriched Gene Ontology and KEGG pathways of hub genes. Genes were analyzed in terms of biological process, cellular component and molecular function. Significantly enriched pathways were identified in the KEGG pathway analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes.](OR-41-03-1586-g08){#f9-or-41-03-1586}

![Enriched BP interaction network of hub genes. BP terms, including 'exogenous drug catabolic process', 'drug catabolic process', 'secondary metabolic process' and 'oxidation reduction', were significantly enriched. BP, biological process.](OR-41-03-1586-g09){#f10-or-41-03-1586}

![Enriched CC interaction network of hub genes. In CC terms, 'subsynaptic reticulum', 'endoplasmic reticulum', 'microsome' and 'vesicular fraction', were enriched. CC, cellular component.](OR-41-03-1586-g10){#f11-or-41-03-1586}

![Enriched MF interaction network of hub genes.'Oxygen binding', 'iron ion binding', 'heme binding', 'electron carrier activity' and 'oxidoreductase activity', were enriched in terms of MF. MF, molecular function.](OR-41-03-1586-g11){#f12-or-41-03-1586}

###### 

Identified hub genes in the GSE36376 dataset and their screening centralities.

  Genes        Degree centralities   Betweenness centralities   Closeness centralities
  ------------ --------------------- -------------------------- ------------------------
  *CYP2E1*     37                    362.1080892                0.009345794
  *TAT*        32                    266.8918244                0.008928571
  *CYP2A6*     32                    97.3346815                 0.008064516
  *CYP8B1*     32                    109.0359712                0.008064516
  *CYP2C9*     31                    179.8498746                0.007874016
  *HSD11B1*    31                    333.8964087                0.008849558
  *HSD17B13*   31                    147.7138107                0.008403361
  *SLC22A1*    30                    84.7381197                 0.008403361
  *CYP2C8*     29                    36.7257238                 0.007751938
  *ADH4*       28                    52.5113332                 0.007575758

*CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *TAT*, tyrosine aminotransferase; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.

###### 

Demographic characteristics of HCC patients.

  Variables      Patients (n=360)   Number (%)   MST (days)   HR (95% CI)         Log-rank P-value
  -------------- ------------------ ------------ ------------ ------------------- ------------------
  Race                                                                            
    Asian        155                44 (28.4)    NA           Ref.                
    Non-Asian    196                78 (39.8)    1,397        1.29 (0.89--1.87)   0.184
  Sex                                                                             
    Male         244                78 (32.0)    2,486        Ref.                
    Female       116                48 (41.4)    1,560        1.21 (0.84--1.73)   0.308
  Age (years)                                                                     
    ≤61          186                59 (31.7)    2,116        Ref.                
    \>61         171                65 (38.0)    1,622        1.18 (0.83--1.69)   0.349
  Tumor stage                                                                     
    I and II     252                66 (26.2)    2,532        Ref.                
    III and IV     87               48 (55.2)      770        2.50 (1.72--3.63)   \<0.0001

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. MST, median survival time; HR, hazard ratio; CI, confidence interval; NA, not available; Ref., reference; Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7.

###### 

Survival analysis of HCC patient prognosis.

  Gene expression   Patients/events   MST (days)   Crude HR (95% CI)   Crude P-value                                             Adjusted HR (95% CI)   Adjusted P-value
  ----------------- ----------------- ------------ ------------------- --------------------------------------------------------- ---------------------- ------------------------------------------------------
  *ADH4*                                                                                                                                                
    Low             180/80            1,372        Ref.                                                                          Ref.                   
    High            180/46            2,456        0.52 (0.36--0.75)   \<0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^    0.55 (0.38--0.81)      0.002^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *CYP2A6*                                                                                                                                              
    Low             180/66            1,694        Ref.                                                                          Ref.                   
    High            180/60            1,791        0.83 (0.58--1.18)   0.291                                                     0.83 (0.57--1.20)      0.321
  *CYP2C8*                                                                                                                                              
    Low             180/75            1,229        Ref.                                                                          Ref.                   
    High            180/51            2,456        0.56 0.39--0.79)    0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.56 (0.38--0.83)      0.003^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *CYP2C9*                                                                                                                                              
    Low             180/74            1,271        Ref.                                                                          Ref.                   
    High            180/52            2,456        0.56 (0.39--0.80)   0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.64 (0.43--0.93)      0.020^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *CYP2E1*                                                                                                                                              
    Low             180/75            1,490        Ref.                                                                          Ref.                   
    High            180/51            2,456        0.67 (0.47--0.96)   0.029^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.74 (0.51--1.08)      0.119
  *CYP8B1*                                                                                                                                              
    Low             180/73            1,372        Ref.                                                                          Ref.                   
    High            180/53            2,131        0.63 (0.44--0.90)   0.010^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.61 (0.42--0.89)      0.011^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *HSD11B1*                                                                                                                                             
    Low             180/71            1,397        Ref.                                                                          Ref.                   
    High            180/55            2,131        0.77 (0.54--1.09)   0.142                                                     0.81 (0.56--1.18)      0.279
  *SLC22A1*                                                                                                                                             
    Low             180/79            1,149        Ref.                                                                          Ref.                   
    High            180/47            2,456        0.49 (0.34--0.70)   \<0.0001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^   0.51 (0.35--0.75)      0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *TAT*                                                                                                                                                 
    Low             180/74            1,372        Ref.                                                                          Ref.                   
    High            180/52            2,131        0.56 (0.39--0.80)   0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.53 (0.36--0.78)      0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^
  *HSD17B13*                                                                                                                                            
    Low             180/74            1,372        Ref.                                                                          Ref.                   
    High            180/52            2,456        0.57 (0.40--0.81)   0.001^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^      0.56 (0.39--0.82)      0.003^[a](#tfn3-or-41-03-1586){ref-type="table-fn"}^

P\<0.05. MST, median survival time; HR, hazard ratio; CI, confidence interval; *CYP2E1*, cytochrome P450 family 2 subfamily E member 1; *TAT*, tyrosine aminotransferase; *CYP2A6*, cytochrome P450 family 2 subfamily A member 6; *CYP8B1*, cytochrome P450 family 8 subfamily B member 1; *CYP2C9*, cytochrome P450 family 2 subfamily C member 9; *HSD11B1*, hydroxysteroid 11-β dehydrogenase 1; *HSD17B13*, hydroxysteroid 17-β dehydrogenase 13; *SLC22A1*, solute carrier family 22 member 1; *CYP2C8*, cytochrome p450 family 2 subfamily C member 8; *ADH4*, alcohol dehydrogenase 4 (class II), pi polypeptide.

###### 

Stratified analysis of *HSD17B13, SLC22A1* and *TAT* for HCC patients (n=360) in terms of prognosis.

                 *HSD17B13*   SLC22A1   *TAT*                                                                                                                                                                                               
  -------------- ------------ --------- ------------------- ------------------------------------------------------ ----- ----- ------------------- -------------------------------------------------------- ----- ----- ------------------- ------------------------------------------------------
  Race                                                                                                                                                                                                                                      
    Asian        87             68      0.48 (0.24--0.93)   0.03^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^    88    67    0.32 (0.15--0.68)   0.003^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^     92    63    0.38 (0.19--0.78)   0.009^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^
    Non-Asian    89           107       0.55 (0.34--0.89)   0.014^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   89    107   0.64 (0.40--1.05)   0.076                                                    82    114   0.66 (0.41--1.07)   0.092
  Sex                                                                                                                                                                                                                                       
    Male         128          116       0.47 (0.28--0.78)   0.003^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   111   133   0.48 (0.29--0.79)   0.004^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^     115   129   0.44 (0.27--0.72)   0.001^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^
    Female       52           64        0.71 (0.39--1.28)   0.258                                                  69    47    0.60 (0.31--1.13)   0.113                                                    65    51    0.79 (0.43--1.45)   0.45
  Age (years)                                                                                                                                                                                                                               
    ≤61          100          86        0.42 (0.24--0.74)   0.003^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   104   82    0.29 (0.16--0.55)   \<0.001^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   103   83    0.37 (0.21--0.67)   0.001^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^
    \>61         80           91        0.66 (0.39--1.12)   0.121                                                  74    97    0.76 (0.45--1.31)   0.325                                                    74    97    0.73 (0.43--1.24)   0.244
  Tumor stage                                                                                                                                                                                                                               
    I and II     121          131       0.61 (0.37--0.99)   0.047^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   116   136   0.55 (0.34--0.91)   0.019^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^     121   131   0.61 (0.37--1.00)   0.048^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^
    III and IV   50           37        0.47 (0.26--0.86)   0.015^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^   58    29    0.40 (0.20--0.79)   0.009^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^     53    34    0.41 (0.21--0.77)   0.006^[a](#tfn5-or-41-03-1586){ref-type="table-fn"}^

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7.

P\<0.05. HR, hazard ratio; 95% CI, 95% confidence interval.

###### 

Stratified analysis of *ADH4, CYP2C8, CYP2C9* and *CYP8B1* for HCC patients (n=360) in terms of prognosis.

                 *ADH4*   CYP2C8   CYP2C9              *CYP8B1*                                                                                                                                                                                                                                                             
  -------------- -------- -------- ------------------- ------------------------------------------------------ ----- ----- ------------------- ------------------------------------------------------ ----- ----- ------------------- ------------------------------------------------------ ----- ----- ------------------- --------------------------------------------------------
  Race                                                                                                                                                                                                                                                                                                                      
    Asian        91       64       0.35 (0.17--0.74)   0.005^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   85    70    0.40 (0.20--0.80)   0.009^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   79    76    0.40 (0.21--0.75)   0.004^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   93    62    0.28 (0.13--0.59)   0.001^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^
    Non-Asian    85       111      0.62 (0.38--1.01)   0.057                                                  92    104   0.70 (0.43--1.13)   0.143                                                  97    99    0.75 (0.45--1.23)   0.251                                                  84    112   0.90 (0.55--1.45)   0.658
  Sex                                                                                                                                                                                                                                                                                                                       
    Male         107      137      0.51 (0.31--0.83)   0.006^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   120   124   0.48 (0.29--0.80)   0.005^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   108   136   0.54 (0.33--0.89)   0.015^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   109   135   0.48 (0.30--0.78)   0.003^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^
    Female       73       43       0.65 (0.34--1.25)   0.196                                                  60    56    0.75 (0.42--1.37)   0.355                                                  72    44    0.85 (0.46--1.58)   0.613                                                  71    45    1.00 (0.54--1.85)   0.998
  Age (years)                                                                                                                                                                                                                                                                                                               
    ≤61          103      83       0.43 (0.24--0.77)   0.005^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   106   80    0.54 (0.30--0.98)   0.044^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   98    88    0.73 (0.42--1.27)   0.269                                                  115   71    0.27 (0.14--0.53)   \<0.001^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^
    \>61         75       96       0.63 (0.36--1.09)   0.096                                                  71    100   0.63 (0.37--1.06)   0.08                                                   79    92    0.62 (0.37--1.06)   0.082                                                  63    108   0.99 (0.58--1.69)   0.973
  Tumor stage                                                                                                                                                                                                                                                                                                               
    I and II     117      135      0.62 (0.38--1.01)   0.055                                                  113   139   0.58 (0.36--0.95)   0.029^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   113   139   0.61 (0.38--1.00)   0.048^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   121   131   0.79 (0.48--1.28)   0.334
    III and IV   53       34       0.45 (0.24--0.84)   0.013^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   59    28    0.50 (0.27--0.95)   0.033^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^   56    31    0.65 (0.35--1.20)   0.171                                                  51    36    0.38 (0.20--0.71)   0.003^[a](#tfn7-or-41-03-1586){ref-type="table-fn"}^

Data were unavailable for race in 9 patients, age in 3 patients and tumor stage in 21 patients. Tumor stage was determined with the Tumor, Node and Metastasis staging system version 7.

P\<0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
